Figure 1

Rosiglitazone inhibits matrix metalloproteinase-1 (MMP-1) and MMP-13 mRNA production in a dose-dependent manner. SW-1353 cells were treated with varying concentrations of rosiglitazone for 24 hours followed by 24 hours of treatment with 1 ng/mL interleukin-1-beta (IL-1β). Total RNA was harvested, and MMP-1 and MMP-13 mRNA levels were quantified using real-time reverse transcription-polymerase chain reaction. Y values are given as molecules of MMP per molecule of GAPDH (glyceraldehyde 3-phosphate dehydrogenase) mRNA. There is no statistical difference between MMP-13 mRNA levels at concentrations of 50 and 500 nM (P = 0.16). P values were calculated for the difference from the IL-1β sample using the Student t test (*P < 0.05, **P < 0.005). NoTx, no treatment; Rosi, rosiglitazone.